Regentis' Cartilage Gel: What the EIC Accelerator Paid For

Regentis Biomaterials has had a product cleared for sale in Europe since August 2017 and has never sold one. GelrinC, a gel that a surgeon pours into a damaged patch of knee cartilage and hardens with ultraviolet light, carries a CE mark, yet the Israeli company states in its 2025 annual report that it has "never generated any revenue from product sales". In January 2019 the European Commission selected Regentis in the EIC SME Instrument Phase 2, the Horizon 2020 forerunner of the EIC Accelerator, and paid €2,185,190 towards CHAMPION, a €3,121,700 project to get GelrinC ready for market, according to CORDIS.

The project ended on 30 September 2023. Of its three goals, a better manufacturing process was achieved, a finished pivotal trial was not, and a European sales channel is only now being built. Regentis listed on the NYSE American in December 2025 at $8 a share, below its planned range, according to Renaissance Capital. On 7 October 2026 the shares traded at $1.69, a market value of $11.87 million, according to StockAnalysis.

A Listed Company With Eight Staff

Regentis is active and listed. It files as a foreign private issuer with the US Securities and Exchange Commission, and those filings are the most detailed public record of the company; an extract from the Israeli Corporations Authority could not be retrieved for this article. The 2025 annual report counts eight employees, six of them in management and one part time. Its auditor, Deloitte Israel, added a going concern qualification to the 2025 accounts, the company said in its 2025 results.

The road to the stock market took three attempts. A first IPO registration filed in November 2022 was withdrawn in November 2024 without any shares sold. In May 2023 Regentis agreed to merge with OceanTech Acquisitions I, a blank-cheque company, in a deal valuing it at $95 million, according to SPACInsider; the merger was terminated in May 2024 after OceanTech failed to meet Nasdaq requirements, the annual report says. The third attempt, a $10 million IPO of 1,250,000 shares, closed on 5 December 2025, according to the company's closing announcement. Renaissance Capital put the market value at pricing at $47 million.

Since the listing, the company has changed chief executive, raised more money at a lower price and dropped a follow-on offering. Chief executive Eli Hazum resigned on 31 December 2025 "for personal reasons", and chairman Ehud Geller took over, according to a filing. A public offering registered in May 2026 was abandoned on 15 June 2026. Two days later Regentis priced a $6.5 million private placement at $3.50 per share with warrants, less than half the IPO price, according to its announcement, also carried by Newswire.

The Technology: A Gel That Fences Off the Wound

Knee cartilage does not heal on its own. The standard treatment, microfracture, drills small holes into the bone beneath the defect so that marrow fills it, but the result is fibrous scar-like tissue that, according to the company, gives relief for eight to fourteen months on average. The alternatives cost more or demand more of the patient: cell therapies such as autologous chondrocyte implantation need two operations and a laboratory to grow the patient's own cells, which Regentis puts at about $40,000 a procedure in the United States, and Agili-C, a coral-based plug that Smith+Nephew bought with CartiHeal for $180 million upfront in January 2024, has to be drilled into the bone.

GelrinC is a hydrogel of polyethylene glycol diacrylate, a polymer used in tissue engineering, and denatured human fibrinogen, a blood-clotting protein. The surgeon fills the defect with the liquid and cures it with ultraviolet light; the whole procedure takes about ten minutes, according to the annual report. The CHAMPION objective on CORDIS describes the claimed mechanism: the implant acts as a barrier that keeps unwanted cells out, while the polymer gives the body's own stem cells an environment in which to turn into cartilage cells, and the gel erodes from the outside in as new "hyaline-like" cartilage replaces it. It needs no cells, no second operation and no bone drilling, which is the core of Regentis' case against its rivals.

The clinical evidence so far comes from a 56-patient pilot study. Two-year MRI results of GelrinC-treated lesions were published in the journal Cartilage in June 2020 by a Vienna team with Siegfried Trattnig as senior author, a paper listed among the CHAMPION results on CORDIS. The company says pain and function scores in that study improved twice as much as in historical microfracture patients. That comparison is the company's own; the pilot study had no randomised control arm.

What CHAMPION Promised, and What CORDIS Shows

The European Commission's list of SME Instrument Phase 2 winners names Regentis as the only beneficiary of CHAMPION. The grant agreement was signed on 23 May 2019 and the project ran from 1 June 2019 to 30 September 2023. The final periodic report sets out three steps to market: optimise the production process, complete a Phase III trial that shows "statistically significant superiority over the standard of care", and create sales channels with a Centre of Excellence in Europe. The two public deliverables were a signed strategic marketing partnership and the launch of the first Centre of Excellence.

The report claims a cleaner, "environmentally friendly" manufacturing process with a new patent application, and a trial running at 18 centres in Europe, the United States and Israel with no adverse effects reported. On the commercial side it says only that Centres of Excellence "have been identified". No marketing partnership was announced. The annual report published in February 2026, more than two years after the project ended, says Regentis "currently" has no strategic partners in Europe.

1. Optimise and scale up manufacturingDeliveredSolvent-free process developed; a US patent was granted in December 2025 and the European Notified Body approved the process in July 2026, with a yield increase of about 400%, the company says.
2. Complete the Phase III pivotal trialNot achieved47 of 80 patients treated in December 2022 and in February 2026; 43 reported in September 2026. No FDA filing yet.
3. Strategic marketing partnershipNot achievedNo partner announced; the 2025 annual report says there is none in Europe.
4. First European Centre of ExcellenceLateOnly "identified" by 2023; surgeon training at Humanitas in Milan was announced in June 2026 for the third quarter of 2026.
5. European market launchNot achievedNo product revenue to date.

That makes CHAMPION partly delivered. The manufacturing work is real and has reached a regulator's approval, three years after the project closed. The two goals that decide whether a cartilage product becomes a business, trial data good enough for the FDA and a way to sell it in Europe, were not met within the project.

A Trial That Has Not Moved Since 2022

Regentis started its pivotal trial under an FDA investigational device exemption in November 2017. The design compares GelrinC with historical microfracture data licensed from TiGenix rather than with a control group, and the FDA has agreed that 80 patients with two years of follow-up are enough for a premarket approval application. In its December 2022 IPO filing Regentis said it had treated 47 patients and would recruit the rest "subject to financing". The 2025 annual report, filed in February 2026, gives the same figure, 47, with 43 of them through their two-year follow-up, and says it expects to file with the FDA by the end of 2027.

The September 2026 half-year release reports a different number: "To date, Regentis has recruited and treated 43 of 80 patients." The filings do not explain why the count is four lower than in February. Earlier releases from December 2025 onwards said enrolment had "surpassed 50%". Whichever figure is right, no new patient has been reported in almost four years, and the target date for full enrolment has moved from the second quarter to the third quarter and now to around the end of 2026. Because the FDA filing needs two years of follow-up after the last patient, an enrolment finish around the end of 2026 no longer fits the annual report's target of a filing by the end of 2027; the September release gives no new filing date.

The Money

The 2024 accounts show the only profit in the company's history, $4.8 million, and it came from the EU. Regentis booked the Horizon 2020 grant, $2.3 million, as a reduction of research costs once the EU approved the project's completion, and repaid a $325,000 bridging loan from shareholders and officers in April 2024 "after receipt of the Horizon 2020 grant", the annual report says. The rest of that year's gain was an accounting change in the value of convertible notes. Research spending was $806,000 in 2023 and $662,000 before the grant in 2024: small sums for a company running a multinational device trial.

The IPO changed the scale. The 2025 net loss of $13.6 million was driven by $5.4 million of share-based pay for the chairman, staff and service providers and by $6.7 million of finance costs, not by research, which cost $331,000. In the first half of 2026 research spending rose to about $1.2 million, against $180,000 a year earlier, and cash stood at $8.95 million on 30 June 2026 after all debt was repaid, according to the interim accounts. The accumulated deficit was $58.4 million.

Why Europe Should Care

Regentis could apply as an Israeli company because Israel has been associated with EU research programmes since 1996 and took part in Horizon 2020 on the same terms as member states; it joined Horizon Europe in December 2021. The project's case for EU money was European patients: CORDIS cites more than one million people a year in Europe with cartilage injuries, and the CE mark meant GelrinC was, in the report's words, "regulatory ready" for Europe.

Seven years after the grant, GelrinC has still not been sold in Europe. The company's 2026 plans point to Europe again: trial sites added in Italy, Germany, Serbia, Slovenia and Romania, and surgeon training in Milan. The private placement announcement lists "Medical Device Regulation compliance" among the uses of the new money. Whether GelrinC's 2017 certificate has already been moved to the EU's newer Medical Device Regulation is not stated in the filings reviewed for this article.

The Verdict

Regentis Biomaterials has not been asked for comment for this article. It is based entirely on public records, company filings and EU project data, linked throughout.